Search

Rocket Pharmaceuticals Inc

Abierto

SectorSanidad

2.48 2.06

Resumen

Variación precio

24h

Actual

Mínimo

2.38

Máximo

2.48

Métricas clave

By Trading Economics

Ingresos

171M

123M

BPA

-0.15

Empleados

202

EBITDA

179M

134M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+289.34% upside

Dividendos

By Acuity

Próximas Ganancias

4 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-147M

250M

Apertura anterior

0.42

Cierre anterior

2.48

Rocket Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

30 oct 2026, 19:53 UTC

Rocket Pharmaceuticals, Inc. shares fell sharply after pulling back from an early session high, remaining above its 20-day moving average.

29 oct 2026, 20:07 UTC

Rocket Pharmaceuticals, Inc. shares declined, pulling back from an earlier peak.

28 oct 2026, 22:21 UTC

Rocket Pharmaceuticals, Inc. shares are lower in after-market trading, reversing earlier gains to reach their lowest point of the day.

27 oct 2026, 20:01 UTC

Rocket Pharmaceuticals, Inc. shares are up sharply, showing strong momentum with a peak return exceeding 10% since Monday's close.

26 oct 2026, 20:07 UTC

Rocket Pharmaceuticals Inc shares are declining, having reached a session low earlier before recovering slightly, but remain below the 20-day moving average.

23 oct 2026, 20:07 UTC

Rocket Pharmaceuticals Inc shares are declining amid a broadly lower market, influenced by mixed economic indicators and rising oil prices raising inflation concerns.

22 oct 2026, 20:07 UTC

Rocket Pharmaceuticals Inc shares are trading sharply higher, rebounding from a recent decline, as the broader market experiences significant upward movement.

21 oct 2026, 22:21 UTC

Rocket Pharmaceuticals Inc. advanced sharply in after-market trading, closing at its peak.

20 oct 2026, 20:21 UTC

Rocket Pharmaceuticals Inc gained sharply in after-market trading, rising since Tuesday's close.

19 oct 2026, 20:07 UTC

Correlated Moves

Rocket Pharmaceuticals shares are higher, supported by positive clinical trial results in the biotech sector, alongside gains in the SPDR S&P Biotech ETF.

16 oct 2026, 21:01 UTC

Rocket Pharmaceuticals Inc shares advanced in after-market hours on Friday.

15 oct 2026, 20:02 UTC

Rocket Pharmaceuticals Inc is trading sharply higher, reversing a recent trend of declines after closing lower in each of the previous four sessions.

13 oct 2026, 20:01 UTC

Rocket Pharmaceuticals Inc shares fell sharply, continuing a downward trend amid broader market weakness, remaining well below their 20-day moving average.

12 oct 2026, 20:06 UTC

Rocket Pharmaceuticals Inc shares are declining, continuing a downward trend since Friday, finishing near session lows and significantly below its 20-day moving average.

9 oct 2026, 21:10 UTC

Rocket Pharmaceuticals Inc is advancing in after-market trading, showing a notable increase since Friday's close while remaining near the lower end of its one-month range.

8 oct 2026, 23:10 UTC

Rocket Pharmaceuticals Inc is trading higher in after-market hours, moving up since Thursday's close despite pulling back from an earlier peak.

7 oct 2026, 20:07 UTC

Social Media
News

Rocket Pharmaceuticals' gene therapy candidate RP-A501 shows promising initial results; shares are higher since Tuesday, despite earlier intraday weakness.

6 oct 2026, 22:01 UTC

News

Rocket Pharmaceuticals secures a $150 million credit facility with Hercules Capital to bolster its financial position and support its Phase 2 study of RP-A501.

5 oct 2026, 20:06 UTC

Rocket Pharmaceuticals Inc is advancing amid a broader market recovery, despite experiencing a significant decline over the past month and remaining near its recent lows.

2 oct 2026, 19:45 UTC

Rocket Pharmaceuticals Inc shares fell sharply, continuing a downward trend since Thursday and remaining significantly below its 20-day moving average.

1 oct 2026, 21:01 UTC

Rocket Pharmaceuticals Inc advanced in after-market trading on Thursday, recovering sharply from earlier losses amid broader market challenges.

30 sept 2026, 20:07 UTC

Rocket Pharmaceuticals Inc is gaining in today's trading session, advancing since Tuesday's close, despite a pullback from earlier session highs.

29 sept 2026, 23:01 UTC

Rocket Pharmaceuticals Inc is trading modestly higher in after-market hours following Tuesday's close, despite a significant decline over the past month.

28 sept 2026, 23:26 UTC

Rocket Pharmaceuticals Inc gained in after-market hours on Monday, recovering from earlier losses, though it remains significantly lower compared to last month's close.

25 sept 2026, 23:56 UTC

Rocket Pharmaceuticals Inc is advancing in after-market trading, gaining significantly since Friday's close after a recent decline over the past month.

24 sept 2026, 20:01 UTC

Rocket Pharmaceuticals Inc shares fell sharply, reaching their lowest point of the day and remaining well below the 20-day moving average.

23 sept 2026, 23:46 UTC

Rocket Pharmaceuticals Inc saw an increase in after-market trading, recovering from an earlier session dip and advancing higher since Wednesday's close.

22 sept 2026, 23:21 UTC

Rocket Pharmaceuticals Inc is seeing a modest increase in after-market trading, building on Tuesday's close, although it remains below its 20-day moving average.

21 sept 2026, 22:06 UTC

Advanced modestly in after-market trading despite economic growth concerns.

18 sept 2026, 22:56 UTC

Rocket Pharmaceuticals Inc is trading higher in after-market hours, maintaining an upward trend since Friday's close despite being below its 20-day moving average.

Comparación entre iguales

Cambio de precio

Rocket Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

289.34% repunte

Estimación a 12 Meses

Media 9.5 USD  289.34%

Máximo 15 USD

Mínimo 4 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Rocket Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

11 ratings

7

Comprar

4

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
help-icon Live chat